New antibody-chemo combo aims to improve ovarian cancer surgery success
NCT ID NCT07432594
First seen Feb 27, 2026 · Last updated Apr 29, 2026 · Updated 6 times
Summary
This study tests whether adding a bispecific antibody (targeting PD-1 and CTLA-4) to standard chemotherapy helps shrink advanced ovarian cancer more before surgery. About 82 people with stage IIIC-IV high-grade serous ovarian cancer who can't have optimal initial surgery will get either chemo alone or chemo plus the antibody. The main goal is to see if more tumors can be completely removed during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.